FBR & Co reissued their outperform rating on shares of Geron Corp. (NASDAQ:GERN) in a research note issued to investors on Thursday. They currently have a $5.00 price target on the biopharmaceutical company’s stock.
A number of other research analysts have also recently issued reports on the stock. BTIG Research reaffirmed a neutral rating on shares of Geron Corp. in a report on Tuesday, September 20th. Piper Jaffray Cos. reiterated an overweight rating and issued a $5.00 price target (down from $10.00) on shares of Geron Corp. in a research report on Tuesday, September 13th. Finally, Zacks Investment Research upgraded shares of Geron Corp. from a hold rating to a strong-buy rating and set a $3.00 price target on the stock in a research report on Friday, August 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $5.00.
Shares of Geron Corp. (NASDAQ:GERN) opened at 2.21 on Thursday. The stock has a market cap of $351.70 million, a price-to-earnings ratio of 276.25 and a beta of 2.63. The firm has a 50-day moving average price of $2.56 and a 200-day moving average price of $2.77. Geron Corp. has a 12 month low of $1.84 and a 12 month high of $5.30.
Geron Corp. (NASDAQ:GERN) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.02. Geron Corp. had a net margin of 3.39% and a return on equity of 0.89%. The company earned $0.21 million during the quarter, compared to analysts’ expectations of $0.38 million. During the same period last year, the company posted ($0.06) earnings per share. The firm’s quarterly revenue was down 15.9% compared to the same quarter last year. Equities analysts expect that Geron Corp. will post ($0.23) EPS for the current fiscal year.
Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Geron Corp. by 8.0% in the second quarter. Vanguard Group Inc. now owns 6,296,230 shares of the biopharmaceutical company’s stock worth $16,874,000 after buying an additional 465,626 shares during the period. Emerald Acquisition Ltd. purchased a new stake in shares of Geron Corp. during the second quarter worth about $1,239,000. Renaissance Technologies LLC purchased a new stake in shares of Geron Corp. during the first quarter worth about $1,324,000. Panagora Asset Management Inc. raised its stake in shares of Geron Corp. by 32.9% in the first quarter. Panagora Asset Management Inc. now owns 1,823,587 shares of the biopharmaceutical company’s stock worth $5,325,000 after buying an additional 451,440 shares during the period. Finally, A.R.T. Advisors LLC raised its stake in shares of Geron Corp. by 59.0% in the first quarter. A.R.T. Advisors LLC now owns 661,334 shares of the biopharmaceutical company’s stock worth $1,931,000 after buying an additional 245,500 shares during the period. Hedge funds and other institutional investors own 38.09% of the company’s stock.
About Geron Corp.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.
Receive News & Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related companies with MarketBeat.com's FREE daily email newsletter.